Company Description
Kenvue Inc. operates as a consumer health company worldwide.
The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health.
The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names.
The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands.
The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
| Country | United States |
| IPO Date | May 4, 2023 |
| Industry | Household & Personal Products |
| Sector | Consumer Staples |
| Employees | 22,000 |
| CEO | Thibaut Mongon |
Contact Details
Address: 199 Grandview Road Skillman, New Jersey 08558 United States | |
| Phone | 908-874-1200 |
| Website | kenvue.com |
Stock Details
| Ticker Symbol | KVUE |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001944048 |
| CUSIP Number | 49177J102 |
| ISIN Number | US49177J1025 |
| Employer ID | 88-1032011 |
| SIC Code | 2844 |
Key Executives
| Name | Position |
|---|---|
| Thibaut Mongon | Chief Executive Officer and Director |
| Paul Ruh | Chief Financial Officer |
| Carlton Lawson | Group President of Europe, Middle East and Africa |
| Ellie Bing Xie | Group President of Asia Pacific |
| Meredith Stevens | Chief Operations Officer |
| Heather R. Howlett | Chief Accounting Officer |
| Bernardo Tavares | Chief Data and Technology Officer |
| Dr. Caroline Tillett | Chief Scientific Officer |
| Tina Romani | Head of Investor Relations |
| Matthew Orlando | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 28, 2024 | 8-K | Current Report |
| May 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 15, 2024 | 424B4 | Prospectus |
| May 14, 2024 | EFFECT | Notice of Effectiveness |
| May 13, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 15, 2024 | DRS | [Cover] Draft Registration Statement |
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |